Edgewise Therapeutics Inc (EWTX)
17.51
-0.40
(-2.23%)
USD |
NASDAQ |
Jun 14, 16:00
17.52
+0.01
(+0.06%)
After-Hours: 20:00
Edgewise Therapeutics Research and Development Expense (TTM): 98.72M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 98.72M |
| December 31, 2023 | 90.90M |
| September 30, 2023 | 79.83M |
| June 30, 2023 | 69.94M |
| March 31, 2023 | 62.78M |
| December 31, 2022 | 54.03M |
| September 30, 2022 | 46.51M |
| Date | Value |
|---|---|
| June 30, 2022 | 42.49M |
| March 31, 2022 | 37.95M |
| December 31, 2021 | 32.19M |
| September 30, 2021 | 28.24M |
| June 30, 2021 | 21.60M |
| March 31, 2021 | 17.38M |
| December 31, 2020 | 14.98M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
14.98M
Minimum
Dec 2020
98.72M
Maximum
Mar 2024
49.83M
Average
44.50M
Median
Research and Development Expense (TTM) Benchmarks
| Pfizer Inc | 10.67B |
| Alnylam Pharmaceuticals Inc | 1.035B |
| Catalyst Pharmaceuticals Inc | 92.17M |
| Cytokinetics Inc | -- |
| Amicus Therapeutics Inc | 139.21M |